Loading...
Search for: human-epidermal-growth-factor-receptor-2
0.005 seconds

    HEROHE Challenge: Predicting HER2 status in breast cancer from hematoxylin–eosin whole-slide imaging

    , Article Journal of Imaging ; Volume 8, Issue 8 , 2022 ; 2313433X (ISSN) Conde Sousa, E ; Vale, J ; Feng, M ; Xu, K ; Wang, Y ; Della Mea, V ; La Barbera, D ; Montahaei, E ; Baghshah, M ; Turzynski, A ; Gildenblat, J ; Klaiman, E ; Hong, Y ; Aresta, G ; Araújo, T ; Aguiar, P ; Eloy, C ; Polónia, A ; Sharif University of Technology
    MDPI  2022
    Abstract
    Breast cancer is the most common malignancy in women worldwide, and is responsible for more than half a million deaths each year. The appropriate therapy depends on the evaluation of the expression of various biomarkers, such as the human epidermal growth factor receptor 2 (HER2) transmembrane protein, through specialized techniques, such as immunohistochemistry or in situ hybridization. In this work, we present the HER2 on hematoxylin and eosin (HEROHE) challenge, a parallel event of the 16th European Congress on Digital Pathology, which aimed to predict the HER2 status in breast cancer based only on hematoxylin–eosin-stained tissue samples, thus avoiding specialized techniques. The... 

    CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

    , Article Cancer Cell International ; Volume 20, Issue 1 , September , 2020 Miri, S. M ; Tafsiri, E ; Cho, W. C. S ; Ghaemi, A ; Sharif University of Technology
    BioMed Central Ltd  2020
    Abstract
    Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients, a so called "adoptive cell transfer", or ACT, process. Construction of allogeneic T-cells is dependent on the employment of a gene-editing tool to modify donor-extracted T-cells and prepare them to specifically act against tumor cells with enhanced function and durability and least side-effects. In this context, CRISPR technology can be used to produce universal T-cells, equipped with recombinant T cell...